| Cutivate Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Cutivate 0.005% | ointment | topical | 100.0 gram(s) | OTC |
| Cutivate 0.05% | lotion | topical | 100.0 milliliter(s) | OTC |
| Cutivate 0.05% | cream | topical | 100.0 gram(s) | OTC |
Ceragenix Commences Second in Series of Clinical Trials - Business Wire (press release)
The Company recently announced results from a 113 person clinical study that compared EpiCeram⢠to Cutivate®, a topical mid-strength steroid in treating the ...
Wed Apr 25 04:54:57 -0400 2007
Ceragenix Commences Second in Series of Clinical Trials - PipelineReview.com (press release)
The Company recently announced results from a 113 person clinical study that compared EpiCeram(TM) to Cutivate(R), a topical mid-strength steroid in ...
Wed Apr 25 19:58:37 -0400 2007
Ceragenix Announces Results from Phase IV Study of EpiCeram(TM ... - Genetic Engineering News (press release)
The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate(R) and 54 patients ...
Tue Apr 24 04:35:04 -0400 2007
fluticasone propionate - The propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, antiinflammatory and antipruritic effects. Binding and activation of the glucocorticoid receptor results in the activation of lipocortin that in turn inhibits cytosolic phospholipase A2, which triggers cascade of reactions involved in synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Secondly, mitogen-activated protein kinase (MAPK) phosphatase 1 is induced, thereby leads to dephosphorylation and inactivation of Jun N-terminal kinase directly inhibiting c-Jun mediated transcription. Finally, transcriptional activity of nuclear factor (NF)-kappa-B is blocked, thereby inhibits the transcription of cyclooxygenase 2, which is essential for prostaglandin production.